Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S is a research paper published in New England Journal of Medicine (2022). On theSindex it has a DataRank of 4.6. It has been cited 251 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.829
From this paper's citation signal
Citation Network Contribution
3.7
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NIAID to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center
Grant: UM1 AI68614
NIAID to the HVTN Statistics and Data Management Center
Grant: UM1 AI68635
NIAID to the HVTN Laboratory Center
Grant: UM1 AI68618
NIAID to the HIV Prevention Trials Network (HPTN) Leadership and Operations Center
Grant: UM1 AI68619
NIAID to the AIDS Clinical Trials Group (ACTG) Leadership and Operations Center
Grant: UM1 AI68636
NIAID to the Infectious Diseases Clinical Research Consortium Leadership Group
Grant: UM1 AI148684
NIAID to the Vaccine and Therapeutic Evaluation Units
Grant: UM1 AI148373
NIAID to the Vaccine and Therapeutic Evaluation Units
Grant: UM1 AI148452
NIAID to the Vaccine and Therapeutic Evaluation Units
Grant: UM1 AI148576
NIAID to the Vaccine and Therapeutic Evaluation Units
Grant: UM1 AI148685
National Institutes of Health
Grant: 3UM1AI148685-02S6
Vaccine and Treatment Evaluation Unit at Saint Louis University
National Institutes of Health
Grant: 3UM1AI068636-19SC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
National Institutes of Health
Grant: 5UM1AI148452-02
Vanderbilt Vaccine and Treatment Evaluation Unit
National Institutes of Health
Grant: 5UM1AI148576-02
Vaccine and Treatment Evaluation Units
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 3UM1AI148373-02S1
Kaiser Washington Vaccine and Treatment Evaluation Unit
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 5UM1AI068619-09
LOC: HIV Prevention Trials Network
National Institutes of Health
Grant: 3UM1AI148684-03S1
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
NIAID NIH HHS
Grant: UM1 AI069476
NIAID NIH HHS
Grant: UM1 AI069432
NIAID NIH HHS
Grant: U01 AI122285
NIAID NIH HHS
Grant: UM1 AI069534
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: R01 AI161175
NIAID NIH HHS
Grant: U01 AI069476
NIAID NIH HHS
Grant: U01 AI069470
NIAID NIH HHS
Grant: S10 AI174104
NIAID NIH HHS
Grant: UM1 AI069470
NIAID NIH HHS
Grant: U01 AI068636
NIAID NIH HHS
Grant: UM1 AI069452
NIAID NIH HHS
Grant: UM1 AI069463
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: UM1 AI068619
NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: UM1 AI068617
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals